General Information of the Compound
Compound ID
CP0390640
Compound Name
1-acetyl-N-{3-[4-(4-carbamoylbenzyl)piperidin-1-yl]propyl}-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
    Show/Hide
Synonyms
1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
AIDS228341
TAK220
TBR-220
TBR220
Tak-220
    Show/Hide
Structure
Formula
C31H41ClN4O3
Molecular Weight
553.147
Canonical SMILES
CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1
    Show/Hide
InChI
InChI=1S/C31H41ClN4O3/c1-22-4-9-28(21-29(22)32)36(31(39)27-12-18-35(19-13-27)23(2)37)15-3-14-34-16-10-25(11-17-34)20-24-5-7-26(8-6-24)30(33)38/h4-9,21,25,27H,3,10-20H2,1-2H3,(H2,33,38)
    Show/Hide
InChIKey
ASSJTMUEFHUKMJ-UHFFFAOYSA-N
Physicochemical Property
logP
4.68362
Rotatable Bonds
9
Heavy Atom Count
39
Polar Areas
86.95
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
4
Complexity
39

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 5275766
SID: 26683798
ChEMBL ID
CHEMBL207004
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00903, C-C chemokine receptor type 5
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000053 COS-7 Chlorocebus aethiops (Green monkey)  1
1
IC50 = 0.42 nM
   TI
   LI
   LO
   TS
CL000011 CHO Cricetulus griseus (Chinese hamster)  1
1
IC50 = 3.5 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( Tak-220 )
Drug Name Tak-220
Company Takeda
Indication
Human immunodeficiency virus-1 infection
Phase 1
Target(s)
C-C chemokine receptor type 5 (CCR5)
Binder